Univdatos Whatsapp
Antiviral Drugs Market

The Antiviral Drugs Market is expected to foresee significant growth. Asia-Pacific to lead the growth!

Antiviral Drugs Market is expected to grow at a CAGR of around 3.4% during the forecast period 2021-2027. The global Antiviral Drugs market is expected to witness robust growth mainly due to the medication of an infectious disease caused by a virus. Viruses are responsible for illnesses such as HIV/AIDS, herpes, hepatitis, and influenza viruses that also lead to reduced the immune system of the body, especially among the middle-aged population. Antiviral drugs are the class of medicines that are used for the treatment of viral infections such as hepatitis, HIV and influenza, and herpes. For instance, as per the global gov, there were approximately 37.7 million people across the globe with HIV in 2020. Of these, 36 million were adults and 1.7 million were children aged 0-14 years. More than half (53%) were women and girls. Among the causes of the rapid increase in the rate of viral infections, it was generally regulated in the form of vaccines. Many therapies are available for the treatment of antiviral drugs including topical, systemic, and injectable modalities.

For a detailed analysis of the market, drivers browse through https://univdatos.com/report/antiviral-drugs-market/

HIV/AIDS is a chronic condition that can have a wide range of effects on a person’s body. In some people, HIV/AIDS can attack the immune system and weakens people’s defense. As per World Health Organization, 36.3 million adults around the world between the ages of 18 and 79 living with HIV at the end of 2020. By 2045, this figure is set to reach XX million people. In Europe, 2.2 million people are living with HIV. This figure will rise to XX million in 2045. However, these figures do not fully reflect the significance of this condition, as around 15% of people in Europe are unaware that they have HIV. Anyone with HIV should have their antibody test checked once per year to ensure they are not developing HIV. Especially common in patients whose immune systems have been severely damaged by HIV.

The COVID-19 pandemic has had an unparalleled impact on the socio-economic and healthcare structure across various countries. During COVID -19 period, people have seen their daily lifestyles change drastically. In addition, the COVID-19 outbreak spread to almost every country, due to which the number of infected patients inflated, which strained countries’ healthcare ecosystem and resources. This is mainly because of the intensifying demand for healthcare facilities, workers, medical equipment, devices, drugs, and research studies. For instance, in May 2020, Cipla Inc. partnered with Gilead Sciences for the production and distribution of remdesivir to treat COVID-19 patients in more than 127 countries. Avoidance of urgent or emergency care was more prevalent among unpaid caregivers for adults, persons with underlying medical conditions, young adults, and persons with disabilities. Thus, restraining market growth to some extent in the year 2020.

For a detailed analysis of the Covid-19 Impact on the market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=19627

Based on drug class, the Antiviral Drugs Market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors and others. In 2020, DNA Polymerase Inhibitors dominated the market and are expected to maintain their dominance throughout the forecast period. This is mainly due to the inhibition of selective polymerases involved in DNA repair and/or translation DNA synthesis as anti-cancer agents. Reverse transcriptase inhibitors are cures used in the management and treatment of HIV. It is in the antiretroviral class of drugs. Moreover, the increasing prevalence of diseases such as HIV from mother to child, hepatitis A, and hepatitis b which are associated with spread from one person to another, is also expected to boost the treatment to hopefully decrease the rate of spreaders.

Based on application, The HIV segment commands the market and held the largest revenue share of XX% in 2020. The segment is expected to observe the fastest growth rate over the divine period. The high frequency of HIV infection connected with a large treatment rate, the existence of branded drugs, and government drives to enlarge the treatment rate are estimated to initiate the market at a higher growth rate. For instance, in 2019, the U.S. government stated the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2030. The hepatitis segment held the second-largest revenue share in 2020. Increasing vaccination in case of hepatitis A and B is hit hard the growth adversely.

Request for a Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=19627

For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, South Korea, Rest of Asia-Pacific); and Rest of World. North America will dominate the market on account of the rising research and development initiatives, increasing incidents of chronic diseases coupled with the rising geriatric population. In addition, the increasing presence of major pharmaceutical companies in the region coupled with their increasing focus on the research and development of new drugs is further expected to propel the market growth.

Antiviral Drugs Market Segmentation

Market Insight, by Drug Class

  • DNA Polymerase Inhibitors
  • Reverse transcriptase inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

Market Insight, by Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

Market Insight, by Distribution Channel

  • Hospitals and Clinics
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Market Insight, by Region

  • North America Antiviral Drugs Market
    • US
    • Canada
    • Rest of North America
  • Europe Antiviral Drugs Market
    • Germany
    • UK
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific Antiviral Drugs Market
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World Antiviral Drugs Market

Top Company Profiles

  • Gilead Sciences
  • AbbVie, Inc.
  • Merck & Co.
  • GlaxoSmithKline plc
  • Aurobindo Pharma Limited.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Cipla, Inc.
  • Mylan N V
  • Bristol-Myers Squibb

Leave A Comment

Select Language